title: [Lipid profile in maintenance haemodialysis].
abstract: BACKGROUND
  The chronic kidney failure is a source of dyslipidemia and accelerated atherosclerosis. No changes in the lipoprotein profile could be reversed by dialysis.
  
  
  OBJECTIVE
  Our aim was to study the lipid disturbances characteristics in end stage renal disease in order to assess their theorical atherogenic potential.
  
  
  METHODS
  The patient population consisted of 36 patients on maintenance haemodialysis. Matched control subjects were recruited among apparently healthy normolipidemic Tunisians. Total cholesterol, triglycerides, high-density-lipoprotein cholesterol, low-density-lipoprotein cholesterol, apolipoprotein AI and apolipoprotein B concentrations were measured.
  
  
  RESULTS
  The triglycerides levels were significantly higher in patient group, unlike the high-density-lipoprotein cholesterol and apolipoprotein AI levels that were significantly reduced. We saw no increase in the levels of low-density-lipoprotein cholesterol and apolipoprotein B. The low-density-lipoprotein cholesterol/high-density-lipoprotein cholesterol ratio result wasn't helpful in the evaluation of the atherogenic risk.
  
  
  CONCLUSIONS
  We confirm the quantitative lipid disorders associated with maintenance haemodialysis. The assessment of cardiovascular risk on the basis of these disorders seems difficult.
authors.affiliation: Laboratoire de biochimie, CHU Habib-Bourguiba, Sfax, Tunisie. jamoussikamel@yahoo.fr
authors.forename: K
authors.initials: K
authors.lastname: Jamoussi
authors.forename: F
authors.initials: F
authors.lastname: Ayedi
authors.forename: N
authors.initials: N
authors.lastname: Abida
authors.forename: K
authors.initials: K
authors.lastname: Kamoun
authors.forename: H
authors.initials: H
authors.lastname: Féki
authors.forename: M N
authors.initials: MN
authors.lastname: Chaabouni
authors.forename: F
authors.initials: F
authors.lastname: Hammouda
authors.forename: I
authors.initials: I
authors.lastname: Bahloul
authors.forename: A
authors.initials: A
authors.lastname: Bellaj
authors.forename: J
authors.initials: J
authors.lastname: Hachicha
authors.forename: F
authors.initials: F
authors.lastname: Ellouz
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000209:etiology*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol